COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The SIM-SOF Trial for Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02168361
Recruitment Status : Completed
First Posted : June 20, 2014
Results First Posted : March 4, 2016
Last Update Posted : March 14, 2016
Information provided by (Responsible Party):
Center For Hepatitis C, Atlanta, GA

Brief Summary:
Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: Pegylated Interferon alfa-2b Drug: Simeprevir Drug: Ribavirin Drug: Sofosbuvir Phase 4

Detailed Description:

Patients can be treatment naive or prior null response to Peg/RBV, and must be genotype subtype 1a.

Must have Child's Class A cirrhosis/compensated and no history of decompensation

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis
Study Start Date : December 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : April 2015

Arm Intervention/treatment
Active Comparator: Standard
Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
Drug: Pegylated Interferon alfa-2b
1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
Other Name: Pegintron

Drug: Ribavirin
1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
Other Name: Ribavirin Ribasphere Ribapak

Drug: Sofosbuvir
12 weeks of combination sofosbuvir and simeprevir
Other Name: Sovaldi

Experimental: Simeprevir + Sofosbuvir
(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
Drug: Simeprevir
150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
Other Name: Olysio

Drug: Sofosbuvir
12 weeks of combination sofosbuvir and simeprevir
Other Name: Sovaldi

Primary Outcome Measures :
  1. Proportion of Participants With Sustained Virologic Response 12 (SVR-12) [ Time Frame: 12 weeks post-therapy ]
    Undetectable virus (sensitive nucleic acid test) in Serum at 3 months post-therapy

Secondary Outcome Measures :
  1. Serum HCV RNA Level [ Time Frame: 4 and 12 weeks into therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic hepatitis c,
  • cirrhosis biopsy-proven, or via fibrotest,
  • CPT score less than 7,
  • genotype 1a,
  • INR 2.3 or less,
  • serum albumin greater than 2.7 gm/dL,
  • total bilirubin less than 3 gm/dL,
  • platelet count 50,000 per cubic milliliter or more
  • GFR >50 ml/min

Exclusion Criteria:

  • non genotype 1a,
  • history of CPT class B or C or decompensation or history of same,
  • HIV or HBV coinfection,
  • prior treatment with boceprevir, telaprevir or any other direct acting antiviral agent,
  • uncontrolled psychiatric or cardiopulmonary disorders,
  • planning pregnancy or unwilling/unable to practice contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02168361

Layout table for location information
United States, Georgia
Center for Hepatitis C
Atlanta, Georgia, United States, 30309
Sponsors and Collaborators
Center For Hepatitis C, Atlanta, GA
Layout table for investigator information
Principal Investigator: Brian L Pearlman, MD Center for Hepatitis C
Publications of Results:
Layout table for additonal information
Responsible Party: Center For Hepatitis C, Atlanta, GA Identifier: NCT02168361    
Other Study ID Numbers: CHC-21
First Posted: June 20, 2014    Key Record Dates
Results First Posted: March 4, 2016
Last Update Posted: March 14, 2016
Last Verified: March 2016
Keywords provided by Center For Hepatitis C, Atlanta, GA:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Interferon alpha-2
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Protease Inhibitors
Enzyme Inhibitors